Investigators demonstrated that silencing the circadian regulator Bmal1 or treating lung epithelial cells with the REV-ERB agonist SR9009 reduced ACE2 expression and inhibited SARS-CoV-2 entry and replication.
[iScience]
Sorry, but the selected Zotpress account can't be found.
